APAC Non-Hodgkin Lymphoma Diagnostics Market - Industry Trends and Forecast to 2030
Description
APAC Non-Hodgkin Lymphoma Diagnostics Market - Industry Trends and Forecast to 2030
The Asia-Pacific non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 8.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Asia-Pacific Non-Hodgkin Lymphoma Diagnostics Market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of Asia-Pacific non-Hodgkin lymphoma diagnostics market are:
• Increased growth in the prevalence of non-Hodgkin lymphoma
• Advancement in artificial intelligence in the diagnosis of non-Hodgkin lymphoma
Market Players
Some of the major players operating in the Asia-Pacific Non-Hodgkin lymphoma diagnostics market are:
• CANON MEDICAL SYSTEMS CORPORATION
• Koninklijke Philips N.V.
• Siemens Healthcare GmbH
• Danaher.
• Bio-Rad Laboratories, Inc.
• General Electric Company
• Sysmex Corporation
• Grail
• F. Hoffmann-La Roche
• Neusoft Corporation
• Agilent Technologies, Inc.
• NeoGenomics Laboratories
• Hologic, Inc
• Integrated DNA Technologies, Inc.
• CENTOGENE N.V.
• Merit Medical Systems
• Invitae Corporation
• PerkinElmer Inc.
• QIAGEN
• GeneDx, LLC
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
Table of Contents
414 Pages
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of The Asia Pacific Non-hodgkin Lymphoma Diagnostics Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Product Type Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Market Application Coverage Grid
- 2.11 Vendor Share Analysis
- 2.12 Secondary Sources
- 2.13 Assumptions
- 3 Executive Summary
- 4 Premium Insights
- 4.1 Pestel Analysis
- 4.2 Porter's 5 Forces
- 5 Industry Insights
- 6 Asia Pacific Non-hodgkin Lymphoma Diagnostics Market, Regulations
- 7 Market Overview
- 7.1 Drivers
- 7.1.1 Increased Growth In Prevalence Of Non-hodgkin Lymphoma
- 7.1.2 Increase In Awareness Regarding Non-hodgkin Lymphoma
- 7.1.3 Advancement In Artificial Intelligence In Diagnosis Of Non-hodgkin Lymphoma
- 7.1.4 Rising Preference For Preventive Health Check-up
- 7.2 Restraints
- 7.2.1 Lack Of Availability Of Trained And Skilled Medical Professionals
- 7.2.2 Stringent Regulations And Guidelines For Different Treatments And Diagnosis
- 7.3 Opportunities
- 7.3.1 Technical Advancements In Cancer Diagnosis
- 7.3.2 Increasing Healthcare Expenditure In Cancer R&D
- 7.3.3 Growing Initiatives By Government And Key Players
- 7.4 Challenges
- 7.4.1 Lack Of Early Diagnostic Awareness Among People
- 7.4.2 High Diagnostic Cost And Fear Of Treatment
- 7.4.3 Common Misdiagnosis Of Non-hodgkin Lymphoma (Nhl)
- 8 Asia Pacific Non-hodgkin Lymphoma Diagnostic Market, By Test Type
- 8.1 Overview
- 8.2 Imaging
- 8.2.1 Computed Tomography (Ct)
- 8.2.2 Chest X-ray
- 8.2.3 Magnetic Resonance Imaging (Mri)
- 8.2.4 Ultrasound
- 8.2.5 Positron Emission Tomography (Pet)
- 8.3 Biopsy
- 8.3.1 Excisional Or Incisional Biopsy
- 8.3.2 Core Needle Biopsy
- 8.4 Immunohistochemistry
- 8.5 Biomarker Test
- 8.5.1 Beta 2-m
- 8.5.2 Ldh
- 8.5.3 Ca-125
- 8.5.4 Tp53
- 8.5.5 Npm1
- 8.5.6 Others
- 8.6 Genetic Test
- 8.7 Cytogenetics
- 8.8 Lumbar Puncture (Spinal Tap)
- 8.9 Blood Test
- 8.10 Cytochemistry
- 8.11 Others
- 9 Asia Pacific Non-hodgkin Lymphoma Diagnostic Market, By Tumor Type
- 9.1 Overview
- 9.2 Aggressive Lymphomas
- 9.2.1 Diffuse Large B Cell Lymphoma
- 9.2.1.1 Instrument Based Products
- 9.2.1.2 Platform Based Products
- 9.2.1.3 Kits And Reagents
- 9.2.1.4 Other Consumables
- 9.2.2 Anaplastic Large-cell Lymphoma
- 9.2.2.1 Instrument Based Products
- 9.2.2.2 Platform Based Products
- 9.2.2.3 Kits And Reagents
- 9.2.2.4 Other Consumables
- 9.2.3 Mantle Cell Lymphoma
- 9.2.3.1 Instrument Based Products
- 9.2.3.2 Platform Based Products
- 9.2.3.3 Kits And Reagents
- 9.2.3.4 Other Consumables
- 9.2.4 Peripheral T-cell Lymphoma
- 9.2.4.1 Instrument Based Products
- 9.2.4.2 Platform Based Products
- 9.2.4.3 Kits And Reagents
- 9.2.4.4 Other Consumables
- 9.2.5 Lymphoblastic Lymphoma
- 9.2.5.1 Instrument Based Products
- 9.2.5.2 Platform Based Products
- 9.2.5.3 Kits And Reagents
- 9.2.5.4 Other Consumables
- 9.2.6 Burkitt Lymphoma
- 9.2.6.1 Instrument Based Products
- 9.2.6.2 Platform Based Products
- 9.2.6.3 Kits And Reagents
- 9.2.6.4 Other Consumables
- 9.3 Indolent Lymphomas
- 9.3.1 Follicular Lymphoma
- 9.3.1.1 Instrument Based Products
- 9.3.1.2 Platform Based Products
- 9.3.1.3 Kits And Reagents
- 9.3.1.4 Other Consumables
- 9.3.2 Cutaneous T-cell Lymphoma
- 9.3.2.1 Instrument Based Products
- 9.3.2.2 Platform Based Products
- 9.3.2.3 Kits And Reagents
- 9.3.2.4 Other Consumables
- 9.3.3 Marginal Zone B Cell Lymphoma
- 9.3.3.1 Instrument Based Products
- 9.3.3.2 Platform Based Products
- 9.3.3.3 Kits And Reagents
- 9.3.3.4 Other Consumables
- 9.3.4 Lymphoplasmacytic Lymphoma
- 9.3.4.1 Instrument Based Products
- 9.3.4.2 Platform Based Products
- 9.3.4.3 Kits And Reagents
- 9.3.4.4 Other Consumables
- 9.3.5 Small-cell Lymphocytic Lymphoma
- 9.3.5.1 Instrument Based Products
- 9.3.5.2 Platform Based Products
- 9.3.5.3 Kits And Reagents
- 9.3.5.4 Other Consumables
- 10 Asia Pacific Non-hodgkin Lymphoma Diagnostic Market, By Application
- 10.1 Overview
- 10.2 Screening
- 10.2.1 Instrument Based Products
- 10.2.2 Platform Based Products
- 10.2.3 Kits And Reagents
- 10.2.4 Other Consumables
- 10.3 Diagnostic And Predictive
- 10.3.1 Instrument Based Products
- 10.3.2 Platform Based Products
- 10.3.3 Kits And Reagents
- 10.3.4 Other Consumables
- 10.4 Prognostic
- 10.4.1 Instrument Based Products
- 10.4.2 Platform Based Products
- 10.4.3 Kits And Reagents
- 10.4.4 Other Consumables
- 10.5 Research
- 10.5.1 Instrument Based Products
- 10.5.2 Platform Based Products
- 10.5.3 Kits And Reagents
- 10.5.4 Other Consumables
- 11 Asia Pacific Non-hodgkin Lymphoma Diagnostics Market, By Cancer Stage
- 11.1 Overview
- 11.2 Stage Iv
- 11.3 Stage I
- 11.4 Stage Iii
- 11.5 Stage Ii
- 11.6 Stage 0
- 12 Asia Pacific Non-hodgkin Lymphoma Diagnostic Market, By Technology
- 12.1 Overview
- 12.2 Fluorescent In Situ Hybridization
- 12.3 Next Generation Sequencing
- 12.4 Fluorimmunoassay
- 12.5 Comparative Genomic Hybridization
- 12.6 Immunohistolochemical
- 12.7 Other
- 13 Asia Pacific Non-hodgkin Lymphoma Diagnostic Market, By Product
- 13.1 Overview
- 13.2 Instrument Based Products
- 13.2.1 Imaging
- 13.2.2 Biopsy
- 13.3 Platform Based Products
- 13.3.1 Next-generation Sequencing
- 13.3.2 Microarrays
- 13.3.3 Pcr
- 13.3.4 Others
- 13.4 Kits And Reagents
- 13.4.1 Non-hodgkin Lymphoma Panels
- 13.4.2 Immunohistochemistry Stains
- 13.4.3 Others
- 13.5 Other Consumables
- 14 Asia Pacific Non-hodgkin Lymphoma Diagnostic Market, By End User
- 14.1 Overview
- 14.2 Hospitals
- 14.3 Diagnostic Centers
- 14.4 Cancer Research Centers
- 14.5 Academic Institutes
- 14.6 Ambulatory Surgical Centers
- 14.7 Others
- 15 Asia Pacific Non-hodgkin Lymphoma Diagnostic Market, By Distribution Channel
- 15.1 Overview
- 15.2 Direct Tender
- 15.3 Retail Sales
- 15.4 Others
- 16 Asia Pacific Non-hodgkin Lymphoma Diagnostics Market, By Region
- 16.1 Asia-pacific
- 16.1.1 China
- 16.1.2 Japan
- 16.1.3 India
- 16.1.4 Australia
- 16.1.5 South Korea
- 16.1.6 Indonesia
- 16.1.7 Philippines
- 16.1.8 Thailand
- 16.1.9 Malaysia
- 16.1.10 Vietnam
- 16.1.11 Singapore
- 16.1.12 Rest Of Asia-pacific
- 17 Asia Pacific Non-hodgkin Lymphoma Diagnostics Market: Company Landscape
- 17.1 Company Share Analysis: Asia Pacific
- 18 Swot Analysis
- 19 Asia Pacific Non-hodkin Lymphoma Diagnostics Market
- 19.1 Canon Medical Systems Corporation
- 19.1.1 Company Snapshot
- 19.1.2 Revenue Analysis
- 19.1.3 Company Share Analysis
- 19.1.4 Product Portfolio
- 19.1.5 Recent Development
- 19.2 Koninklijke Philips N.V.
- 19.2.1 Company Snapshot
- 19.2.2 Revenue Analysis
- 19.2.3 Company Share Analysis
- 19.2.4 Product Portfolio
- 19.2.5 Recent Developments
- 19.3 Siemens Healthcare Gmbh
- 19.3.1 Company Snapshot
- 19.3.2 Revenue Analysis
- 19.3.3 Company Share Analysis
- 19.3.4 Product Portfolio
- 19.3.5 Recent Development
- 19.4 Danaher.
- 19.4.1 Company Snapshot
- 19.4.2 Revenue Analysis
- 19.4.3 Company Share Analysis
- 19.4.4 Product Portfolio
- 19.4.5 Recent Developments
- 19.5 Bio-rad Laboratories, Inc.
- 19.5.1 Company Snapshot
- 19.5.2 Revenue Analysis
- 19.5.3 Company Share Analysis
- 19.5.4 Product Portfolio
- 19.5.5 Recent Development
- 19.6 Agilent Technologies, Inc.
- 19.6.1 Company Profile
- 19.6.2 Revenue Analysis
- 19.6.3 Product Portfolio
- 19.6.4 Recent Development
- 19.7 Centogene N.V.
- 19.7.1 Company Snapshot
- 19.7.2 Product Portfolio
- 19.7.3 Recent Development 389
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
